Treatment with BIBF1120 capsules lung carcinoma patients with an abnormal fibroblast growth factor-1 receptor (NVALT15)
- Conditions
- on-small cell lung cancer (NSCLC).
- Registration Number
- NL-OMON28108
- Lead Sponsor
- ederlandse Vereniging van Artsen voor Longziekten en Tuberculose NVALT (dutch society of pulmonary physicians)
- Brief Summary
one
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
•Stage IIIB or IV after failure of first line treatment or recurrent NSCLC haboring a positive FISH for FGFR1 amplification.
•Age ≥ 18 years.
Exclusion Criteria
•Other investigational drugs or treatment in another clinical trial within the past 4 weeks.
•Chemo-, hormone-, immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival.
- Secondary Outcome Measures
Name Time Method Response rate, duration of response, overall survival, safety and tolerability.